Chidiebere Joshua Nwankwo

Mx. Chidiebere Joshua Nwankwo


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
CEChinedu Ogbonnia Egwu
Chinedu Ogbonnia Egwu
CAChinyere Aloke
Chinyere Aloke
JCJennifer Ifeoma Chukwu
Jennifer Ifeoma Chukwu
CNChidiebere Joshua Nwankwo
Chidiebere Joshua Nwankwo
CIChinemerem Irem
Chinemerem Irem
NONwogo Ajuka Obasi
Nwogo Ajuka Obasi
The fight against malaria is a continuum as the epidemic is not abating. For proper deployment of tools in the fight against malaria, an assessment of the situation is necessary. This work assessed the level of antimalarial drug treatment failure in Ebonyi State, Nigeria. Both survey and in vitro analyses were adopted. The survey was used to obtain qualitative information from both the malaria subjects and the pharmacies where antimalarial drugs are sourced. The results from the survey were complemented by an in vitro assay of the level of active pharmaceutical ingredients (APIs) in the commonly used artemisinin combination in Nigeria; artemether/lumefantrine. Results from the survey revealed that artemisinin combination therapies (ACTs) remain the mainstay in the treatment of malaria, even though other non-artemisinin drugs are still used. It also revealed that many patients still self-medicate, although, this may not be connected to the treatment failure seen among some malaria subjects. The in vitro assay showed that ACT contains the right quantity of APIs. Further surveillance is, therefore, necessary to understand the real cause of treatment failure among malaria subjects in Nigeria.